LY4152199 - IV

Phase 1Small molecule

Eli Lilly

LY4152199 - IV is one of 10 small molecule programs targeting Lymphoma, Non-Hodgkin. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoma, Non-HodgkinNot yet recruiting

Lymphoma, Non-HodgkinPhase 1

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Lymphoma, Non-Hodgkin

#DrugCompanyPhaseTrials

JNJ-80948543

Johnson & Johnson

Phase 1

3 2

Opdualag

Bristol-Myers Squibb

Preclinical

1 3

Opdivo

Bristol-Myers Squibb

Preclinical

1 4

JNJ-75348780

Johnson & Johnson

Phase 1

2 5

DZD8586

DDizal Pharmaceuticals

Phase 1

1 6

MK-1045

Merck & Co.

Preclinical

1 7

JNJ-87801493

Johnson & Johnson

Phase 1

2 8

JNJ-88998377

Johnson & Johnson

Phase 1

1 9

LY4152199 - IV

Eli Lilly

Phase 1

1 10

Prizloncabtagene Autoleucel

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Lymphoma, Non-Hodgkin

NCT07101328

Clinical

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07101328·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LY4152199 - IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4152199 - IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4152199 - IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eli Lilly

LY4152199 - IV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Lymphoma, Non-Hodgkin1 trial

References

Drug Info

Quick Facts

Related News